Clinical Trials Browser

Neoplasm, Residual × Plasma cell × 1 year × Clear all

NCT06993675 2026-05-13

ROTATE

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Phase 1/2 Active not recruiting

35 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT05690984 2026-03-16

EMAT

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual

NCT02389517 2026-01-22

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Phase 2 Completed

42 enrolled 11 charts

Multiple Myeloma, Neoplasm, Residual

NCT05625971 2026-01-07

NIRVANA

Neoplasm, Residual, Neoplasms, Plasma Cell

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT07045168 2025-09-15

Risk-adapted Therapeutic Strategy in +1q NDMM

Not yet recruiting

Multiple Myeloma, Neoplasm, Residual